Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Receivables - Other: 2009-2025

Historic Receivables - Other for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $7.0 million.

  • Lifecore Biomedical's Receivables - Other rose 71.52% to $7.0 million in Q2 2025 from the same period last year, while for May 2025 it was $7.0 million, marking a year-over-year increase of 71.52%. This contributed to the annual value of $7.0 million for FY2025, which is 71.52% up from last year.
  • Per Lifecore Biomedical's latest filing, its Receivables - Other stood at $7.0 million for Q2 2025, which was up 13.48% from $6.2 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical's Receivables - Other peaked at $13.9 million during Q1 2022, and registered a low of $2.9 million during Q4 2023.
  • Over the past 3 years, Lifecore Biomedical's median Receivables - Other value was $4.1 million (recorded in 2023), while the average stood at $4.5 million.
  • In the last 5 years, Lifecore Biomedical's Receivables - Other slumped by 69.25% in 2023 and then soared by 96.48% in 2024.
  • Lifecore Biomedical's Receivables - Other (Quarterly) stood at $12.6 million in 2021, then slumped by 33.33% to $8.4 million in 2022, then tumbled by 65.48% to $2.9 million in 2023, then skyrocketed by 96.48% to $5.7 million in 2024, then skyrocketed by 71.52% to $7.0 million in 2025.
  • Its Receivables - Other stands at $7.0 million for Q2 2025, versus $6.2 million for Q1 2025 and $5.7 million for Q4 2024.